ASRS 2019 Street Team: Raj K. Maturi, MD

Article
Conference|ASRS

ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process

Raj K. Maturi, MD, discusses phase II data from the abicipar Phase II MAPLE Trial for patients with AMD at the 2019 annual ASRS conference.

Related Videos
Marion Munk, MD, PhD, presenting slides
Marion Munk, MD, PhD, presenting slides
Related Content
Outlook Therapeutics submits UK Marketing Authorization Application for wet AMD treatment

Outlook Therapeutics submits UK Marketing Authorization Application for wet AMD treatment

May 15th 2024
Article
Putting in practice retina innovations amid a pandemic

Putting in practice retina innovations amid a pandemic

August 28th 2020
Podcast
India-based Eyestem receives approval to commence human trial for Eyecyte RPE for AMD

India-based Eyestem receives approval to commence human trial for Eyecyte RPE for AMD

April 14th 2024
Article
EyePod

ASRS 2020: Evaluating 3-year-recurrence rate in non-infectious posterior segment uveitis post-FAi

July 29th 2020
Podcast
John Han, PharmD named Vice President, Medical Affairs for Opthea Limited

John Han, PharmD named Vice President, Medical Affairs for Opthea Limited

April 10th 2024
Article
Clinical trials: Companies tackle AMD in early 2024

Clinical trials: Companies tackle AMD in early 2024

April 2nd 2024
Article
© 2024 MJH Life Sciences

All rights reserved.